Scott M. Lippman, MD
Professor of Medicine
Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care
Chugai Pharmaceutical Chair in Cancer
Scott M. Lippman, MD, brings more than 25 years of experience as principal investigator of translational research involving investigator-initiated clinical trials and maintains an active clinical practice. As a clinician, he is well-respected by his peers, with recognition in every major “Top Doctor” listing including
U.S. News & World Report. His research interests include clinical and translational research focused on head and neck and lung cancer; genetic drivers of cancer; predictive molecular signatures, biomarkers for clinical response in solid tumors; design of trials using molecular targets and markers for cancer prevention and therapy. Since 1990, he has had continuous funding from the National Cancer Institute (NCI), including as principal investigator of major programmatic grants to develop personalized or precision medicine. He received The University of Texas MD Anderson Cancer Center team science award for his leadership of the multidisciplinary molecular-guided Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial for lung cancer.
Dr. Lippman is Director of Moores Cancer Center at UC San Diego Health, the only NCI-designated comprehensive cancer center in the region. He is Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care, Professor of Medicine, Chugai Pharmaceutical Chair and adjunct professor at the Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute and MD Anderson Cancer Center. Prior to arriving at Moores Cancer Center in 2012, Dr. Lippman was chair of the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center.
Dr. Lippman has participated in the national leadership of clinical and translational research planning and development within the National Cancer Institute Cooperative Group setting and currently sits on the NCI Clinical Trials and Translational Research Advisory Committee (CTAC). He chairs the CTAC Clinical Trials Strategic Planning subcommittee and is chair of the NCI Chemo/Dietary Prevention Study Section. He serves on several NCI advisory boards, NCI cancer center external advisory boards and journal editorial boards. Dr. Lippman has served on the United States Food and Drug Administration Oncologic Drugs Advisory Committee and was elected to the board of directors for the American Association for Cancer Research (AACR), Association of American Cancer Institutes and National Comprehensive Cancer Network.
Dr. Lippman completed fellowships in hematology and medical oncology at Stanford University and University of Arizona and internship and residency in internal medicine at Johns Hopkins Hospital and Harbor-UCLA Medical Center. He received his medical degree from Johns Hopkins University School of Medicine and is triple-board certified in internal medicine, hematology and medical oncology.
Author of more than 350 publications in high-impact journals, including The New England Journal of Medicine, JAMA, PNAS, and The Lancet, and chapters in major medical textbooks, Dr. Lippman has received many awards, among them the American Society of Clinical Oncology (ASCO)-American Cancer Society Award, AACR Cancer Research and Prevention Foundation Award, and the ASCO Statesman Award, and was elected to the Association of American Physicians, the most prestigious physician-scientist society in the world.
Director's Office contact information